聚乙二醇与乳果糖治疗肝性脑病患者疗效和安全性的Meta分析

doi:10.3969/j.issn.1672-5069.2021.01.026

Abstract

Abstract: Objective The aim of this study was to meta-analyzed the randomized controlled trials(RCTs) of polyethylene glycol (PEG) and lactulose in the treatment of patients with hepatic encephalopathy (HE). Methods The meta-analysis was conducted in PubMed, EMbase,Cochrane,WanFang Data and CNKI by computer search and retrieve untill November 20,2019. RCTs were selected and their quality was evaluated by RevMan 5.3 software. Results A total of 8 randomized controlled studies were obtained, including 249 patients in the PEG group and 244 patients in the lactulose group; the results of Meta analysis showed that the incidence of adverse reactions in PEG group was 12.9%, significantly lower than that in lactulose group(27.4%, P＜0.0001); the improvement rate of 24-hour HESA score in PEG group was 91.5%, significantil higher than 65.5% in lactulose group (P＜0.0001); the hospital stay in PEG group and lactulose group was ,and serum ammonia decreased after treatment were in the two groups. Conclution Compared with lactulose intervention, the administration of PEG has fewer adverse reactions in patients with HE, which might decrease 24-hour HESA score, shorten hospital stay, and needs further investigation.

Key words: Hepatic encephathy, Polyethylene glycol, Lactulose, Meta-analysis, Therapy

Zeng Jiao, Guo Guihai. Efficacy and safety of polyethylene glycol and lactulose in the treatment of patients with hepatic encephalopathy:a Meta-analysis[J]. Journal of Practical Hepatology, 2021, 24(1): 99-102.

References

[1] Vilstrup H,Amodio P,Bajaj J,et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. Hepatology,2014,60(2):715-735.
[2] Fleming KM,Aithal GP,Solaymani-Dodaran M,et al. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: A general population-based study. J Hepatol,2008,49(5):732-738.
[3] Bannister CA,Orr JG,Reynolds AV,et al. Natural history of patients taking rifaximin-alpha for recurrent hepatic encephalopathy and risk of future overt episodes and mortality: A post-hoc analysis of clinical trials data. Clin Ther,2016,38(5):1081-1089.e1084.
[4] Sawhney R,Jalan R. Liver: The gut is a key target of therapy in hepatic encephalopathy. Nat Rev Gastroenterol Hepatol,2015,12(1):7-8.
[5] 李明强,王砚砚,徐德魁. 乳果糖联合聚乙二醇辅助治疗肝性脑病的疗效观察. 中国实用医药,2015,10(33):168-169.
[6] 钟天胜. 聚乙二醇-电解质溶液在肝性脑病中的应用效果观察. 中外医学研究,2016,14(22):9-10.
[7] 严涛,江振,钟金妹,等. 复方聚乙二醇电解质散在治疗肝性脑病中的疗效观察. 医学理论与实践,2016,29(10):1268-1270.
[8] 汤泗玲. 聚乙二醇-电解质溶液在肝性脑病中的应用效果观察. 中国现代药物应用,2017,11(22):120-121.
[9] Naderian M,Akbari H,Saeedi M,et al. Polyethylene glycol and lactulose versus lactulose alone in the treatment of hepatic encephalopathy in patients with cirrhosis: A non-inferiority randomized controlled trial. Middle East J Dig Dis,2017,9(1):12-19.
[10] Bajwa KN,Aziz B,Nazar T. Comparison of the effectiveness and safety profile of polyethylene glycol-electrolyte solution with lactulose in patients of overt hepatic encephalopathy. Pakistan J Med Healt Sci,2019,13(2):411-414.
[11] Shehata H,Elfert AA,Abdin AA,et al. Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy. Eur J Gastroenterol Hepatol,2018,30(12):1476-1481.
[12] Rahimi RS,Singal AG,Cuthbert JA,et al. Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: The help randomized clinical trial. JAMA Intern Med,2014,174(11):1727-1733.
[13] Romero-Gomez M,Montagnese S,Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol,2015,62(2):437-447.
[14] 彭思璐,刘冰,孙宏,等. HBV相关慢加急性肝衰竭患者预后及其影响因素分析. 实用肝脏病杂志,2019,22(4):545-548.
[15] 马雅琼,李芝兰,夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变. 实用肝脏病杂志,2019,22(6):892-895.
[16] Sidhu SS,Sharma BC,Goyal O,et al. L-ornithine l-aspartate in bouts of overt hepatic encephalopathy. Hepatology,2018,67(2):700-710.
[17] Nardelli S,Lattanzi B,Merli M,et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis. Hepatology,2019,70(5):1704-1713.
[18] Vierling JM,Mokhtarani M,Brown RS, Jr.,et al. Fasting blood ammonia predicts risk and frequency of hepatic encephalopathy episodes in patients with cirrhosis. Clin Gastroenterol Hepatol,2016,14(6):903-906.
[19] Jarzebicka D,Sieczkowska-Golub J,Kierkus J,et al. Peg 3350 versus lactulose for treatment of functional constipation in children: Randomized study. J Pediatr Gastroenterol Nutr,2019,68(3):318-324.
[20] Wang Z,Chu P,Wang W. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy. Drug Des Devel Ther,2019,13(17):1-11.

Efficacy and safety of polyethylene glycol and lactulose in the treatment of patients with hepatic encephalopathy:a Meta-analysis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.
[2]	Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.
[3]	Zheng Zhiheng, Li Weiyun, Hui Zhenyu,et al. Serological and virological response topegylated interferon α-2a and entecavir combination in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 19-22.
[4]	Lin Jinxiang, Yang Keli. Comparison of response toPEG-IFNα-2a or PEG-IFNα-2b in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 27-30.
[5]	Fan Bingdong, Zhang Guohua, Wang Jun. An observation of clinical efficacy of sofosbuvir/vipatavir and ribavirin combination in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 31-34.
[6]	Yang Xiaodong,Jia Ting,Zhang Xiuling, et al. Short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 35-38.
[7]	Wei Xiuqin, Yan Xiaoxia, Shi Guorong, et al. Short-termefficacy of atorvastatin and tiopronin combination in the treatment of patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(1): 47-50.
[8]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[9]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[10]	Chen Yanping, Huang Shaoqiang,Deng Xin ,et al. Short-term efficacy of tiopronin and polyene phosphatidylcholine combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 67-70.
[11]	Cai Yu, Wang Mengchun, Qiu Xinping, et al. Improvement of liver function and subsiding jaundice by compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis [J]. Journal of Practical Hepatology, 2021, 24(1): 71-74.
[12]	Wu Chang,Tian Yuan,Liu Hongyan. Short-term efficacy of live clostridium butyricum in assisting tiopronin and metadoxine in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 75-78.
[13]	Li Qingling, He Shuguang, Yi Xiaoming, et al. Changes of peripheral blood lymphocyte PD-1 and PD-L1 expression in patients with autoimmune hepatitis receiving tripterygium wilfordii polyglycosides and magnesium iso-glycyrrhizate [J]. Journal of Practical Hepatology, 2021, 24(1): 79-82.
[14]	Fan Jing, Xu Jing, Yuan Xue. Combination of rifaximin and lactulose improves clinical efficacy and mortality in hepatitis B cirrhotic patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(1): 103-106.
[15]	Zhang Hua, Sun Baofeng, Liu Shiqi. Combination of oxaliplatin and capecitabine plus bevacizumab in conversion treatment of patients with colon cancer and liver metastasis [J]. Journal of Practical Hepatology, 2021, 24(1): 107-110.